Data / Drug companies / Concord Biotech Limited
Concord Biotech Limited: 44 products in the FDA NDC directory, labeler code 68254
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Concord Biotech Limited (labeler code 68254) lists 44 products in the FDA National Drug Code Directory, covering 5 finished drugs by generic name. By type: 33 bulk ingredients, 11 prescription drugs. Its main marketing category is bulk ingredients. The newest product started marketing on October 1, 2026.
The request: Watch Concord Biotech Limited (FDA labeler code 68254): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 68254
- Products in commercial distribution
- 44
- Packages
- 66
- Finished drugs by generic name
- 5
- Prescription products
- 11
- Over the counter products
- 0
- Flagged as original packager
- 9 of 9 products that carry the flag
- Started marketing in the last 12 months
- 3
- Earliest marketing start
- January 1, 2006
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Bulk ingredients | 33 | 75% |
| Generic drugs (ANDA) | 11 | 25% |
Products by type
| Type | Products | Share |
|---|---|---|
| Bulk ingredients | 33 | 75% |
| Prescription drugs | 11 | 25% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Tacrolimus | 3 | 35 |
| Teriflunomide | 2 | 17 |
| Mycophenolic acid | 2 | 16 |
| Mycophenolate mofetil | 2 | 37 |
| Tofacitinib citrate | 2 | 7 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Powder | 33 | 75% |
| Capsule | 4 | 9.1% |
| Tablet, film coated | 4 | 9.1% |
| Tablet, delayed release | 2 | 4.5% |
| Tablet | 1 | 2.3% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
| Class | Products |
|---|---|
| Antimetabolite Immunosuppressant | 4 |
| Calcineurin Inhibitor Immunosuppressant | 3 |
| Pyrimidine Synthesis Inhibitor | 2 |
| Janus Kinase Inhibitor | 2 |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Tofacitinib citrate | 68254-5012 | Tablet, film coated | Generic drugs (ANDA) | October 1, 2026 |
| Tofacitinib citrate | 68254-5011 | Tablet, film coated | Generic drugs (ANDA) | October 1, 2026 |
| Endoxifen citrate | 68254-0024 | Powder | Bulk ingredients | January 5, 2026 |
| Teriflunomide | 68254-5013 | Tablet, film coated | Generic drugs (ANDA) | July 7, 2025 |
| Teriflunomide | 68254-5010 | Tablet, film coated | Generic drugs (ANDA) | July 7, 2025 |
| Polymyxin b sulfate | 68254-2507 | Powder | Bulk ingredients | October 8, 2024 |
| Voclosporin | 68254-0023 | Powder | Bulk ingredients | January 1, 2024 |
| Fidaxomicin | 68254-0022 | Powder | Bulk ingredients | December 1, 2023 |
| Mycophenolate mofetil | 68254-2508 | Powder | Bulk ingredients | November 9, 2023 |
| Nystatin | 68254-2506 | Powder | Bulk ingredients | October 8, 2023 |
| Mycophenolate mofetil | 68254-5003 | Tablet | Generic drugs (ANDA) | December 21, 2020 |
| Tacrolimus | 68254-5006 | Capsule | Generic drugs (ANDA) | November 23, 2020 |
| Tacrolimus | 68254-5005 | Capsule | Generic drugs (ANDA) | November 23, 2020 |
| Tacrolimus | 68254-5004 | Capsule | Generic drugs (ANDA) | November 23, 2020 |
| Mycophenolic acid | 68254-5002 | Tablet, delayed release | Generic drugs (ANDA) | December 13, 2019 |
| Mycophenolic acid | 68254-5001 | Tablet, delayed release | Generic drugs (ANDA) | December 13, 2019 |
| Midostaurin | 68254-0021 | Powder | Bulk ingredients | November 1, 2019 |
| Tacrolimus | 68254-0020 | Powder | Bulk ingredients | October 16, 2019 |
| Mycophenolate mofetil | 68254-5000 | Capsule | Generic drugs (ANDA) | October 1, 2019 |
| Dactinomycin | 68254-0017 | Powder | Bulk ingredients | May 16, 2016 |
| Mitomycin | 68254-0016 | Powder | Bulk ingredients | May 16, 2016 |
| Pimecrolimus | 68254-0014 | Powder | Bulk ingredients | August 1, 2014 |
| Mycophenolate mofetil | 68254-0015 | Powder | Bulk ingredients | July 1, 2014 |
| Anidulafungin | 68254-0013 | Powder | Bulk ingredients | July 1, 2014 |
| Micafungin sodium | 68254-0012 | Powder | Bulk ingredients | May 13, 2014 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.